Dietary Supplement Listing Act of 2026

This bill amends the Federal Food, Drug, and Cosmetic Act to require manufacturers, packers, or distributors of dietary supplements to list their products with the Food and Drug Administration (FDA), improving transparency and information availability. It establishes a new section 403D in the Act, detailing listing requirements, timing, a product listing number, a public electronic database, and confidentiality protections.

Sec. 2, Dietary supplement listing requirement: Starting on a specified date, each dietary supplement marketed in the U.S. must be listed with the FDA. The responsible person (or a U.S. agent if foreign) must submit information including the supplement's name, brand, flavors, responsible person's name and address, U.S. agent details (if foreign), label copy, full ingredient list (including proprietary blend ingredients, with amounts per serving for proprietary blends kept confidential), servings per container, directions for use, warnings, allergen statements, product form, certain health claims, and the product listing number. The FDA may require electronic submission and will notify the responsible person if a listing is complete or incomplete. A single listing can cover multiple supplements with identical formulations or same-form formulations differing only in color, excipients, or flavorings, in one or multiple package sizes. For supplements on the market on or before January 1, 2027, listings must be submitted within 18 months of enactment, and labels must include the listing number within 2 years. New supplements must be listed at introduction, with the listing number on the label. Discontinued supplements must be reported within 1 year. Changes to listings must be submitted when the changed supplement is first introduced. Upon FDA request, the responsible person must provide within 5 calendar days the business names and addresses of manufacturing, packaging, labeling, or holding locations, and sources of dietary ingredients or the supplement.

Sec. 2, Product listing number and electronic database: The FDA will assign a product listing number to each listed supplement, which can apply to multiple identical or similar supplements. The FDA must establish a public electronic database within 2 years of enactment, containing most listing information except responsible person and U.S. agent names/addresses, and proprietary blend ingredient amounts per serving. The database must be searchable by listing number and other fields. Confidential information (responsible person/U.S. agent details, proprietary blend amounts, and additional location/source information) is exempt from public disclosure under FOIA.

Sec. 2, Rule of construction: This section does not limit FDA inspection or recordkeeping authority, authorize disclosure prohibited by other laws, release in the public database information identifying a specific person or facility not on the label or quantities of proprietary blend ingredients, or grant FDA authority to require pre-market approval of dietary supplements.

Sec. 2, Authorization of appropriations: $7,872,984 is authorized for fiscal year 2026, and $6,615,000 for each of fiscal years 2027 through 2030, for activities under this section and hiring personnel.

Sec. 2, Misbranding: A dietary supplement is considered misbranded if the responsible person or U.S. agent fails to comply with the listing, change, or additional information requirements under section 403D.